Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.33) by ...

Canaccord Genuity analyst Kyle Mikson maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $32 to $25.

Those interested in building Alzheimer's disease (AD) testing infrastructure should contact Quanterix to discuss potential ...

Scotiabank analyst Sung Nam maintains Quanterix (NASDAQ:QTRX) with a Sector Outperform and raises the price target from $30 ...

Quanterix Corporation (NASDAQ:QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, a...

2024 Full Year Business OutlookManagement expects full-year 2024 revenue to be in the range of $139 to $144 million. This guide...

Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.32) b...

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...